19. Artificial Antigen-Presenting Cells: Large Multivalent Immunogens

  1. W. John W. Morrow PhD, DSc, FRCPath2,
  2. Nadeem A. Sheikh PhD3,
  3. Clint S. Schmidt PhD4 and
  4. D. Huw Davies PhD5
  1. Matthew F. Mescher PhD and
  2. Julie M. Curtsinger PhD

Published Online: 20 JUN 2012

DOI: 10.1002/9781118345313.ch19

Vaccinology: Principles and Practice

Vaccinology: Principles and Practice

How to Cite

Mescher, M. F. and Curtsinger, J. M. (2012) Artificial Antigen-Presenting Cells: Large Multivalent Immunogens, in Vaccinology: Principles and Practice (eds W. J. W. Morrow, N. A. Sheikh, C. S. Schmidt and D. H. Davies), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781118345313.ch19

Editor Information

  1. 2

    Seattle, WA, USA

  2. 3

    Dendreon Corporation, Seattle, WA, USA

  3. 4

    NovaDigm Therapeutics, Inc., Grand Forks, ND, USA

  4. 5

    University of California at Irvine, Irvine, CA, USA

Author Information

  1. Department of Laboratory Medicine & Pathology, Center for Immunology, University of Minnesota, Minneapolis, MN, USA

Publication History

  1. Published Online: 20 JUN 2012
  2. Published Print: 3 AUG 2012

ISBN Information

Print ISBN: 9781405185745

Online ISBN: 9781118345313



  • antigen;
  • artificial antigen-presenting cell;
  • CD8 T cell;
  • cytokine;
  • delivery;
  • immunotherapy;
  • vaccine;
  • T lymphocyte;
  • tumor


Live cells engineered to express antigen and other stimulatory molecules can be used effectively to stimulate ex vivo expansion of T lymphocytes for adoptive therapies. Acellular constructs having stimulatory molecules displayed on the surfaces of inert particles are also being used for this purpose, but in addition have the potential for in vivo use as vaccines to stimulate immune responses. Tumor vaccine immunotherapy trials using one such construct termed large multivalent immunogen (LMI) have demonstrated the safety of this application.